The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure,” Prof. Marilyn S. Jorns of Drexel University College of Medicine, Principal Investigator
Doylestown, PA. April 21, 2017- FCCDC is pleased to announce that it has been awarded a Phase I STTR entitled “Inhibitors of Hydrogen Sulfide Metabolism as a Novel Treatment for Heart Failure” (R41 HL134435-01A1), Prof. Marilyn S. Jorns of Drexel University College of Medicine, Principal Investigator.